Liquid Biopsy Market, by Sample Type, By Technology (Multi-gene-parallel Analysis, and Single Gene Analysis ), By Biomaker, By Application, By Technology, and By Geography - Analysis, Share, Trends, Size, & Forecast From 2020 - 2026
|発行||AnalystView Market Insights||商品コード||941384|
|出版日||ページ情報||英文 198 Pages
|リキッドバイオプシー（液体生検）市場：サンプルタイプ、技術（多遺伝子並列分析、単一遺伝子分析）、バイオメーカー、用途、技術、 地域別の分析、シェア、動向、規模、予測（2020年～2026年） Liquid Biopsy Market, by Sample Type, By Technology (Multi-gene-parallel Analysis, and Single Gene Analysis ), By Biomaker, By Application, By Technology, and By Geography - Analysis, Share, Trends, Size, & Forecast From 2020 - 2026|
|出版日: 2020年06月01日||ページ情報: 英文 198 Pages||
TABLE Middle East and Africa Liquid Biopsy market, by Biomaker, 2015-2026 (USD Million)
Liquid biopsy Market was valued at USD 49.72 million by 2019, growing with 14.6% CAGR during the forecast period, 2020-2026
Liquid biopsy is a non-invasive and easy method used to diagnose onset of cancer. Liquid biopsy is also called as fluid phase biopsy or fluid biopsy. With liquid biopsy tumors and mutations can be easily tracked over a period of time. For cancer treatment, safety and efficiency is improved by the use of these tests because of their ability to predict treatment outcome, execute apt therapeutic targets, and characterize new lesions.
The growing number of patients being diagnosed with several types of cancer and the advantages of liquid biopsy such as metastatic relapse and minimally invasive are the major factors driving the growth of global liquid biopsy market. According to World Health Organization (WHO), cancer is the second leading cause of death all over the world. Around 9.6 million deaths in 2018 were due to various types of cancer. Moreover, minimally invasive therapies are highly preferred by patients and a surge in disposable income is also witnessed among cancer patients, which is anticipated to propel the market growth during the forecast period. In addition, an increase in healthcare expenditure in the emerging economies such as China and India and growing use of biopsy tests are likely to create lucrative opportunities in the global industry. However, unclear regulation & reimbursement scenario and availability of alternatives to liquid biopsies are predicted to restrict the market growth in the coming future.
Sample Type Takeaway
Blood sample-based is anticipated to grow at a significant rate during the forecast period owing to numerous methods for purification and preexisting applications. Microvesicles, exosomes, circulating tumor cells, and cell-free DNA can be detected in blood samples. In the saliva-based sample type, the next generation sequencing technology is used for detecting multiple mutations in multiple genes. As per certain studies plasma and saliva measurements are corelated, which potentially presents that detection of oncogenic gene mutations.
CTC biomarkers segment is estimated to hold the largest market share in the forecast period owing to accurate tracking results and high awareness levels of cancerous cells in the human body. The number of circulating tumor DNA (ctDNA) and circulating tumor cells (CTC) based liquid biopsy tests that are commercialized are 8-10. The CTC tests are applicable through biochemical marker analysis for classification of tumor cells through. CTC detection, isolation, and molecular characterization systems find tentative application in pancreatic, prostate, colon, breast, head, skin, neck, and lung cancer.
The multi-gene-parallel analysis (NGS) segment is expected to subjugate the worldwide market owing to its capability to denote diagnosis of multiple diseases at one time. Clinical pharmacogenomics tests are taken away by multigene tests from conventional sequencing of single genes, which is marked as a noteworthy step towards detailed analysis of cancer genome. This technology helps oncologists in guiding patients to the targeted therapy by detecting the genetic aberrations. On the other hand, the single gene analysis-based or PCR-based sequencing is employed for analyzing mutations in particular genes with the help of NGS multiplex testing.
The therapy selection for metastatic breast cancer segment is anticipated to witness a considerable growth in the estimated period owing to growing prevalence of metastatic caner all across the globe. It is estimated that liquid biopsy will find application in the molecular monitoring diagnostic, which can be investigated using various biofluids such as saliva, urine, CSF, and blood for patient screening during the forecast period.
Presently, the North America region dominated the global liquid biopsy market in 2018 owing to increasing incidence of cancer and growing need for screening in this region. Europe is estimated to be the second-largest market due to recent regulatory CE approvals for commercial use of liquid biopsy tests.
Key Vendors Takeaway
The major players functioning in the global market are applying several strategies such as mergers & acquisitions and product launches to increase their market share. Some of the prominent players include Guardant Health, Biocept, Personal Genome Diagnostics, Adaptive Biotechnologies, NeoGenomics Laboratories, Cynvenio, Qiagen, RainDance Technologies, and Trovagene.
The market size and forecast for each segment and sub-segments has been considered as below:
Historical Year - 2015 to 2018
Base Year - 2019
Estimated Year - 2020
Projected Year - 2026
Traders, Distributors, and Suppliers
Government and Regional Agencies
Scope of the Report
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL LIQUID BIOPSY MARKET KEY PLAYERS
Personal Genome Diagnostics
GLOBAL LIQUID BIOPSY MARKET, BY SAMPLE TYPE
GLOBAL LIQUID BIOPSY MARKET, BY TECHNOLOGY
Multi-gene-parallel Analysis (NGS)
Single Gene Analysis (PCR Microarrays)
GLOBAL LIQUID BIOPSY MARKET, BY BIOMARKER
Circulating Tumor DNA (ctDNA)
Circulating Tumor Cells (CTC)
GLOBAL LIQUID BIOPSY MARKET, BY APPLICATION
Molecular Health Monitoring
Therapy Selection for Metastatic Breast Cancer (MBS)
Therapy Selection for Other Metastatic Cancer
GLOBAL LIQUID BIOPSY MARKET, BY REGION
Rest of Europe
Rest of APAC
Rest of LATAM
Middle East and Africa
United Arab Emirates
Rest of MEA